Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18/05/2026			5-day change	1st Jan Change
54.62 ^CNY	-3.40%		-9.18%	-19.76%

05-15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT

Tranche Update on Gan & Lee Pharmaceuticals.'s Equity Buyback Plan announced on September 6, 2024.

Published on 10/09/2024

S&P Capital IQ

GAN & LEE PHARMACEUTICALS.

-3.40%

From September 5, 2024 to September 30, 2024, the company has repurchased 396,900 shares, representing 0.07% for CNY 15.13 million. With this, the company has completed the repurchase of 396,900 shares, representing 0.07% for CNY 15.13 million under the buyback announced on September 6, 2024.

Latest news about Gan & Lee Pharmaceuticals.

05-15	Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes	CI
05-07	Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe	MT
04-22	Gan & Lee Pharmaceuticals 2025 net profit up 86.1% y/y	RE
04-22	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1062 Injection	MT
04-15	Gan & Lee Pharmaceuticals' Subsidiary Doses First Subject for Phase III of GZR33 Injection Trial; Shares Up 3%	MT
04-09	Gan & Lee Pharmaceuticals - signs exclusive license agreement with JW Pharmaceutical	RE
04-09	Gan & Lee Pharmaceuticals and Jw Pharmaceutical Sign Exclusive License Agreement for Bofanglutide Injection in South Korea	CI
04-08	Gan & Lee Pharmaceuticals Gets Regulatory Approval for Diabetes Combo Drug	MT
04-07	Gan & Lee Pharmaceuticals Doses First Patient in Prostate Cancer Drug Trial	MT
03-31	Gan & Lee Pharmaceuticals Announces Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints In Two Pivotal Phase 3 Clinical Trials	CI
03-25	Gan & Lee Pharmaceuticals Gets Drug Trial Approval to Treat Obesity-Related Sleep Apnea	MT
03-03	Gan & Lee Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Drug Trials	MT
01-22	Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%	MT
01-15	Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4%	MT

Chart Gan & Lee Pharmaceuticals.

Duration

Period

603087: Dynamic Chart

Company Profile

Gan & Lee Pharmaceuticals is a China-based company primarily engaged in the research, development, production, and sales of insulin analogue active pharmaceutical ingredients and injectable formulations. The Companyâ€™s main products include glargine insulin injection, lispro insulin injection, mixed protamine zinc lispro insulin injection, aspart insulin injection, aspart 30 insulin injection, and mixed protamine human insulin injection. The Company is also engaged in the provision of medical device products, including reusable pen insulin injectors, non-reusable pen injectors, disposable injection pen needles, and disposable insulin pen needles. The Company distributes its products within the domestic market and to overseas markets.

Employees

5,309

Sector

Pharmaceuticals

More about the company